- Home
- Publications
- Publication Search
- Publication Details
Title
The next generation of evidence-based medicine
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 29, Issue 1, Pages 49-58
Publisher
Springer Science and Business Media LLC
Online
2023-01-17
DOI
10.1038/s41591-022-02160-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- External Control Arms in Oncology: Current Use and Future Directions
- (2022) P.S. Mishra-Kalyani et al. ANNALS OF ONCOLOGY
- AI in health and medicine
- (2022) Pranav Rajpurkar et al. NATURE MEDICINE
- Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs
- (2022) Goli Samimi et al. Cancer Prevention Research
- Real-World Evidence — Where Are We Now?
- (2022) John Concato et al. NEW ENGLAND JOURNAL OF MEDICINE
- Think Globally, Act Locally: Globalizing Precision Oncology
- (2022) Justin T. Moyers et al. Cancer Discovery
- A lightspeed approach to pandemic drug development
- (2022) Annaliesa S. Anderson NATURE MEDICINE
- Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
- (2022) Vivek Subbiah et al. NATURE MEDICINE
- Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs
- (2022) David Ochoa et al. NATURE REVIEWS DRUG DISCOVERY
- Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer
- (2022) Sanjay Popat et al. Nature Communications
- The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage
- (2022) Gilberto Morgan et al. Cancer Discovery
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
- (2022) Vivek Subbiah et al. LANCET ONCOLOGY
- Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial
- (2022) Konstantinos D. Rizas et al. NATURE MEDICINE
- Multimodal biomedical AI
- (2022) Julián N. Acosta et al. NATURE MEDICINE
- Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals
- (2022) Yuzhe Yang et al. NATURE MEDICINE
- Artificial intelligence can improve patients’ experience in decentralized clinical trials
- (2022) Kevin A. Thomas et al. NATURE MEDICINE
- Accelerated approvals hit the target in precision oncology
- (2022) Vivek Subbiah et al. NATURE MEDICINE
- A Review of Generalizability and Transportability
- (2022) Irina Degtiar et al. Annual Review of Statistics and Its Application
- Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non–Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment
- (2022) Sreeram V. Ramagopalan et al. JAMA Network Open
- FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
- (2021) Denise Casey et al. CLINICAL CANCER RESEARCH
- Using digital twins in viral infection
- (2021) Reinhard Laubenbacher et al. SCIENCE
- Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: The Fitbit heart study
- (2021) Steven A. Lubitz et al. AMERICAN HEART JOURNAL
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- (2021) Justin F Gainor et al. LANCET ONCOLOGY
- The role of machine learning in clinical research: transforming the future of evidence generation
- (2021) E. Hope Weissler et al. Trials
- Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective
- (2021) Keith T. Flaherty et al. Cancer Discovery
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- (2021) Vivek Subbiah et al. Lancet Diabetes & Endocrinology
- Clinical development times for innovative drugs
- (2021) Dean G. Brown et al. NATURE REVIEWS DRUG DISCOVERY
- Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data
- (2021) Samantha Wilkinson et al. JAMA Network Open
- The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine
- (2020) Dane Dickson et al. CELL
- Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
- (2020) Olivier J. Wouters et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
- (2020) Vivek Subbiah et al. Cancer Discovery
- Snapshot: Trial Types in Precision Medicine
- (2020) Dane Dickson et al. CELL
- The RECOVERY Platform
- (2020) Sharon-Lise T. Normand NEW ENGLAND JOURNAL OF MEDICINE
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
- (2020) Nicholas C Turner et al. LANCET ONCOLOGY
- Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension
- (2020) Xiaoxuan Liu et al. NATURE MEDICINE
- Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension
- (2020) Samantha Cruz Rivera et al. NATURE MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, observational, interventional, and real‐world—What's in a name?
- (2020) John Concato et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
- (2020) Mary W Redman et al. LANCET ONCOLOGY
- Prototype of running clinical trials in an untrustworthy environment using blockchain
- (2019) Daniel R. Wong et al. Nature Communications
- How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology
- (2019) Chayakrit Krittanawong et al. Personalized Medicine
- Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study
- (2019) Philipp Kickingereder et al. LANCET ONCOLOGY
- Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist
- (2019) Jacob J. Adashek et al. ONCOLOGIST
- Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database
- (2019) Stéphanie Nguengang Wakap et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease
- (2019) David C. Fajgenbaum et al. JOURNAL OF CLINICAL INVESTIGATION
- Mobile Health Technology for Atrial Fibrillation Screening Using Photoplethysmography-Based Smart Devices: The HUAWEI Heart study
- (2019) Yutao Guo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Innovation and Opportunities in Pediatric Therapeutic Development
- (2019) Susan McCune et al. Therapeutic Innovation & Regulatory Science
- Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
- (2019) Marco V. Perez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug Regulation in the Era of Individualized Therapies
- (2019) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
- (2019) Jinkuk Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols
- (2019) Jay J. H Park et al. Trials
- Digital twins to personalize medicine
- (2019) Bergthor Björnsson et al. Genome Medicine
- Selective RET kinase inhibition for patients with RET-altered cancers
- (2018) V Subbiah et al. ANNALS OF ONCOLOGY
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- High-performance medicine: the convergence of human and artificial intelligence
- (2018) Eric J. Topol NATURE MEDICINE
- Multidimensional Evidence Generation and FDA Regulatory Decision Making
- (2017) Jonathan P. Jarow et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Accelerating development of scientific evidence for medical products within the existing US regulatory framework
- (2017) Rachel E. Sherman et al. NATURE REVIEWS DRUG DISCOVERY
- Academic, Foundation, and Industry Collaboration in Finding New Therapies
- (2017) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
- (2017) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers and Surrogate Endpoints
- (2016) Melissa A. Robb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Innovation in the pharmaceutical industry: New estimates of R&D costs
- (2016) Joseph A. DiMasi et al. JOURNAL OF HEALTH ECONOMICS
- FDA's Expedited Approval Mechanisms for New Drug Products
- (2015) Erin E. Kepplinger BIOTECHNOLOGY LAW REPORT
- Fast-tracking novel drugs in pediatric oncology
- (2015) Vivek Subbiah CELL CYCLE
- Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm
- (2011) Paul Wicks et al. NATURE BIOTECHNOLOGY
- The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
- (2011) Elizabeth O Lillie et al. Personalized Medicine
- Translational research: Crossing the valley of death
- (2008) Declan Butler NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started